Insider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) CEO Buys $54,810.00 in Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor acquired 14,500 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were bought at an average cost of $3.78 per share, with a total value of $54,810.00. Following the completion of the acquisition, the chief executive officer now directly owns 152,072 shares of the company’s stock, valued at $574,832.16. The trade was a 10.54 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $4.12 on Friday. Perspective Therapeutics, Inc. has a 12-month low of $2.28 and a 12-month high of $19.05. The firm has a 50 day moving average of $10.78 and a 200 day moving average of $12.32.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). The firm had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. Sell-side analysts predict that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

Several large investors have recently made changes to their positions in the business. Janus Henderson Group PLC purchased a new position in shares of Perspective Therapeutics in the first quarter worth $15,511,000. FMR LLC increased its holdings in Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after acquiring an additional 5,370,392 shares during the last quarter. Vanguard Group Inc. lifted its stake in Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares in the last quarter. Nicholson Wealth Management Group LLC bought a new position in shares of Perspective Therapeutics during the 3rd quarter valued at about $21,390,000. Finally, State Street Corp grew its position in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on CATX. UBS Group initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price for the company. Wedbush reiterated an “outperform” rating and set a $11.00 price objective (down previously from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $24.00 to $5.00 in a research report on Monday. Truist Financial began coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 price target for the company. Finally, Oppenheimer dropped their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.14.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.